GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » Net Income From Continuing Operations

Genesystem Co (XKRX:363250) Net Income From Continuing Operations : ₩-8,219.1 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genesystem Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Genesystem Co's net income from continuing operations for the three months ended in Mar. 2024 was ₩-2,342.6 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-8,219.1 Mil.

Genesystem Co Net Income From Continuing Operations Historical Data

The historical data trend for Genesystem Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genesystem Co Net Income From Continuing Operations Chart

Genesystem Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-4,041.00 -2,224.06 3,551.44 -8,996.17 -8,059.01

Genesystem Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,182.49 -1,952.45 -2,283.82 -1,640.25 -2,342.60

Genesystem Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-8,219.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genesystem Co (XKRX:363250) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:950200 XKRX:122310 XKRX:253840 XKRX:086040 XKRX:051980 XKRX:245620 XKRX:153710 XKRX:221800 XKRX:347740 XKRX:031860 TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH
Traded in Other Exchanges
N/A
Address
200-9, Techno 2-ro, Yuseong-gu, Daejeon, KOR, 34028
Website
http://www.genesystem.co.kr
Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.

Genesystem Co (XKRX:363250) Headlines

No Headlines